Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JAMES T PETERSON

Allopathic & Osteopathic Physicians Obstetrics & Gynecology Obstetrics

NPI
1316962442
CMS profile
331955
Location
SALT LAKE CITY, UT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$2,385.11

70 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $1,200.00 1
Food and Beverage $1,165.11 68
Gift $20.00 1

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 2; records 51–70 of 70 matching records. This page contains 20 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JAMES T PETERSON

NPI 1316962442 · CMS profile ID 331955

Allopathic & Osteopathic Physicians / Obstetrics & Gynecology / Obstetrics

SALT LAKE CITY, UT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–70 of 70 matching records. This page contains 20 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1316962442?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JAMES T PETERSON, NPI 1316962442, CMS profile ID 331955. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–70 of 70 matching records. This page contains 20 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1316962442?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). JAMES T PETERSON, NPI 1316962442, CMS profile ID 331955. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–70 of 70 matching records. This page contains 20 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1316962442?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
JAMES T PETERSON, NPI 1316962442, CMS profile ID 331955, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–70 of 70 matching records. This page contains 20 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1316962442?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

70 matching records · $2,385.11 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 70 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–70 of 70.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amarin Pharma Inc. $14.4805/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815274823 CMS
Novo Nordisk Inc $11.5804/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810860254 CMS
BOSTON SCIENTIFIC CORPORATION $17.7504/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 777700519 CMS
GlaxoSmithKline, LLC. $15.4504/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802923713 CMS
Takeda Pharmaceuticals U.S.A., Inc. $17.1303/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820147927 CMS
Biohaven Pharmaceuticals, Inc. $12.7903/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852590127 CMS
Novo Nordisk Inc $13.8703/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810860247 CMS
Amarin Pharma Inc. $12.4703/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815210893 CMS
AstraZeneca Pharmaceuticals LP $11.6503/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829632309 CMS
AbbVie Inc. $24.0403/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795617393 CMS
Amarin Pharma Inc. $14.4403/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815050103 CMS
AbbVie Inc. $4.4102/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795617387 CMS
Takeda Pharmaceuticals U.S.A., Inc. $15.2502/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820147921 CMS
AstraZeneca Pharmaceuticals LP $11.7402/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829553261 CMS
AbbVie Inc. $24.9502/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795617381 CMS
AbbVie Inc. $15.2902/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795617375 CMS
Takeda Pharmaceuticals U.S.A., Inc. $14.0801/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820147915 CMS
Dynavax Technologies Corporation $9.8501/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 800990741 CMS
GlaxoSmithKline, LLC. $14.1601/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802035581 CMS
Novo Nordisk Inc $12.5901/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811387105 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,156.48 91
PY2020 $1,006.60 67
PY2021 $2,385.11 70
PY2022 $1,529.53 85
PY2023 $1,302.85 83
PY2024 $1,515.83 85
PY2025 $990.83 60

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,439,541.56 358
PY2024 Recipient $6,258.51 12
PY2024 Principal investigator $2,839,707.80 547
PY2023 Recipient $3,920.00 4
PY2023 Principal investigator $3,094,774.97 228
PY2022 Recipient $4,600.00 2
PY2022 Principal investigator $3,020,277.43 422
PY2021 Recipient $7,670.00 4
PY2021 Principal investigator $4,728,078.37 431
PY2020 Recipient $8,210.00 4
PY2020 Principal investigator $2,099,134.68 174
PY2019 Principal investigator $2,146,118.67 271

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

358 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $250.00 12/31/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine with an Open-Label Extension No dispute reported 06/30/2026 1202534451
Principal investigator 1 PFIZER INC. $15,746.40 12/31/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A BNT162B2 LP81ADAPTED VACCINE IN CHILDREN 5 THROUGH 11 YEARS OF AGE CONSIDERED AT HIGH RISK FOR SEVERE COVID19 No dispute reported 06/30/2026 1228719769
Principal investigator 1 PFIZER INC. $6,562.20 12/31/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228735703
Principal investigator 1 Ipsen Innovation $956.34 12/23/2025 Non-covered Recipient Entity
J Lewis Research, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291228
Principal investigator 1 Ipsen Innovation $1,182.33 12/23/2025 Non-covered Recipient Entity
J Lewis Research, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291230
Principal investigator 1 PFIZER INC. $4,050.00 12/23/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228746887
Principal investigator 1 SANOFI PASTEUR INC. $2,000.00 12/19/2025 Non-covered Recipient Entity
J Lewis Research,incorporation
A Phase 3 Randomized, Modified Double-blind, Active-controlled Study to Assess the Safety of vYF, Yellow Fever Vaccine, in Adults Aged 18 Years up to 60 Years No dispute reported 06/30/2026 1226099600
Principal investigator 1 SANOFI PASTEUR INC. $935.55 12/19/2025 Non-covered Recipient Entity
J Lewis Research,incorporation
A Phase 3 Randomized, Modified Double-blind, Active-controlled Study to Assess the Safety of vYF, Yellow Fever Vaccine, in Adults Aged 18 Years up to 60 Years No dispute reported 06/30/2026 1226099606
Principal investigator 1 PFIZER INC. $52,772.06 12/17/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE No dispute reported 06/30/2026 1228707323
Principal investigator 1 PFIZER INC. $23,287.50 12/17/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228747013
Principal investigator 1 Ipsen Innovation $200.00 12/15/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291226
Principal investigator 1 PFIZER INC. $587.50 12/15/2025 Non-covered Recipient Entity
J Lewis Research IncFoothill Family Clinic
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN STUDY TO DESCRIBE THE SAFETY AND TOLERABILITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS No dispute reported 06/30/2026 1228718421
Principal investigator 1 Ipsen Innovation $150.00 12/12/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184294605
Principal investigator 1 Ipsen Innovation $180.00 12/11/2025 Non-covered Recipient Entity
J Lewis Research, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184294603
Principal investigator 1 PFIZER INC. $1,219.40 12/10/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228726006
Principal investigator 1 PFIZER INC. $61,784.90 12/09/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A BNT162B2 LP81ADAPTED VACCINE IN CHILDREN 5 THROUGH 11 YEARS OF AGE CONSIDERED AT HIGH RISK FOR SEVERE COVID19 No dispute reported 06/30/2026 1228751143
Principal investigator 1 PFIZER INC. $757.50 12/08/2025 Non-covered Recipient Entity
Foothill Family Clinic J Lewis Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228723904
Principal investigator 1 PFIZER INC. $1,170.00 12/08/2025 Non-covered Recipient Entity
Foothill Family Clinic J Lewis Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228727829
Principal investigator 1 ModernaTX, Inc. $250.00 12/05/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine No dispute reported 06/30/2026 1252963653
Principal investigator 1 ModernaTX, Inc. $4,605.46 12/05/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine No dispute reported 06/30/2026 1252963681
Principal investigator 1 ModernaTX, Inc. $100.00 12/05/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine No dispute reported 06/30/2026 1252963723
Principal investigator 1 ABBVIE INC. $15,000.00 12/04/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202528314
Principal investigator 1 ModernaTX, Inc. $15,312.38 12/01/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252963737
Principal investigator 1 Ipsen Innovation $956.34 11/28/2025 Non-covered Recipient Entity
J Lewis Research, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291216
Principal investigator 1 Ipsen Innovation $956.34 11/28/2025 Non-covered Recipient Entity
J Lewis Research, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291218
Principal investigator 1 Ipsen Innovation $2,567.16 11/28/2025 Non-covered Recipient Entity
J Lewis Research, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291220
Principal investigator 1 Ipsen Innovation $1,182.33 11/28/2025 Non-covered Recipient Entity
J Lewis Research, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291222
Principal investigator 1 Ipsen Innovation $3,112.49 11/28/2025 Non-covered Recipient Entity
J Lewis Research, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291224
Principal investigator 1 PFIZER INC. $27,337.50 11/27/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228730476
Principal investigator 1 PFIZER INC. $15,300.00 11/27/2025 Non-covered Recipient Entity
JLewis Research Inc
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN STUDY TO DESCRIBE THE SAFETY AND TOLERABILITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS No dispute reported 06/30/2026 1228737588
Principal investigator 1 PFIZER INC. $9,231.57 11/26/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE No dispute reported 06/30/2026 1228707247
Principal investigator 1 PFIZER INC. $29,681.50 11/26/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228726824
Principal investigator 1 PFIZER INC. $4,168.00 11/26/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228728321
Principal investigator 1 PFIZER INC. $4,050.00 11/20/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228738694
Principal investigator 1 PFIZER INC. $1,400.00 11/19/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228730140
Principal investigator 1 PFIZER INC. $6,711.45 11/18/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228720771
Principal investigator 1 PFIZER INC. $175.50 11/14/2025 Non-covered Recipient Entity
J Lewis Res Foothill Clnc
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A BNT162B2 LP81ADAPTED VACCINE IN CHILDREN 5 THROUGH 11 YEARS OF AGE CONSIDERED AT HIGH RISK FOR SEVERE COVID19 No dispute reported 06/30/2026 1228723906
Principal investigator 1 PFIZER INC. $222.90 11/14/2025 Non-covered Recipient Entity
J Lewis Res Foothill Clnc
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A BNT162B2 LP81ADAPTED VACCINE IN CHILDREN 5 THROUGH 11 YEARS OF AGE CONSIDERED AT HIGH RISK FOR SEVERE COVID19 No dispute reported 06/30/2026 1228728357
Principal investigator 1 SANOFI PASTEUR INC. $6,420.89 11/14/2025 Non-covered Recipient Entity
J Lewis Research,incorporation
A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers No dispute reported 06/30/2026 1226099563
Principal investigator 1 PFIZER INC. $35,227.08 11/13/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE No dispute reported 06/30/2026 1228707245
Principal investigator 1 PFIZER INC. $272.70 11/12/2025 Non-covered Recipient Entity
J Lewis Research Inc North
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN STUDY TO DESCRIBE THE SAFETY AND TOLERABILITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS No dispute reported 06/30/2026 1228722580
Principal investigator 1 PFIZER INC. $221.58 11/12/2025 Non-covered Recipient Entity
J Lewis Research Inc North
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN STUDY TO DESCRIBE THE SAFETY AND TOLERABILITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS No dispute reported 06/30/2026 1228729669
Principal investigator 1 PFIZER INC. $16,752.70 11/11/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228724434
Principal investigator 1 ModernaTX, Inc. $998.40 11/07/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine No dispute reported 06/30/2026 1252963649
Principal investigator 1 ModernaTX, Inc. $501.80 11/07/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine No dispute reported 06/30/2026 1252963715
Principal investigator 1 PFIZER INC. $95,616.36 11/05/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE No dispute reported 06/30/2026 1228707325
Principal investigator 1 SANOFI PASTEUR INC. $919.58 10/31/2025 Non-covered Recipient Entity
J Lewis Research,inc
Controlled Study of Immunogenicity and Safety of the Investigational vYF Candidate Vaccine in Comparison to YF-VAX in Adults No dispute reported 06/30/2026 1226100354
Principal investigator 1 SANOFI PASTEUR INC. $919.58 10/31/2025 Non-covered Recipient Entity
J Lewis Research,inc
Controlled Study of Immunogenicity and Safety of the Investigational vYF Candidate Vaccine in Comparison to YF-VAX in Adults No dispute reported 06/30/2026 1226100359
Principal investigator 1 SANOFI PASTEUR INC. $919.58 10/31/2025 Non-covered Recipient Entity
J Lewis Research,inc
Controlled Study of Immunogenicity and Safety of the Investigational vYF Candidate Vaccine in Comparison to YF-VAX in Adults No dispute reported 06/30/2026 1226100363
Principal investigator 1 Ipsen Innovation $29.16 10/30/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291188
Principal investigator 1 Ipsen Innovation $101.25 10/30/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291198
Principal investigator 1 Ipsen Innovation $29.16 10/30/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291200
Principal investigator 1 Ipsen Innovation $101.25 10/30/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291204
Principal investigator 1 Ipsen Innovation $101.25 10/30/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291208
Principal investigator 1 PFIZER INC. $148.60 10/30/2025 Non-covered Recipient Entity
J Lewis Res Foothill Clnc
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A BNT162B2 LP81ADAPTED VACCINE IN CHILDREN 5 THROUGH 11 YEARS OF AGE CONSIDERED AT HIGH RISK FOR SEVERE COVID19 No dispute reported 06/30/2026 1228723912
Principal investigator 1 PFIZER INC. $117.00 10/30/2025 Non-covered Recipient Entity
J Lewis Res Foothill Clnc
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A BNT162B2 LP81ADAPTED VACCINE IN CHILDREN 5 THROUGH 11 YEARS OF AGE CONSIDERED AT HIGH RISK FOR SEVERE COVID19 No dispute reported 06/30/2026 1228729191
Principal investigator 1 ModernaTX, Inc. $400.00 10/29/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine No dispute reported 06/30/2026 1252963677
Principal investigator 1 Ipsen Innovation $2,153.79 10/27/2025 Non-covered Recipient Entity
J Lewis Research, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291186
Principal investigator 1 Ipsen Innovation $2,567.16 10/27/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291190
Principal investigator 1 Ipsen Innovation $101.25 10/27/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291192
Principal investigator 1 Ipsen Innovation $2,567.16 10/27/2025 Non-covered Recipient Entity
J Lewis Research, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291194
Principal investigator 1 Ipsen Innovation $101.25 10/27/2025 Non-covered Recipient Entity
J Lewis Research, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291196
Principal investigator 1 Ipsen Innovation $3,112.49 10/27/2025 Non-covered Recipient Entity
J Lewis Research, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291202
Principal investigator 1 Ipsen Innovation $2,458.35 10/27/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291206
Principal investigator 1 Ipsen Innovation $3,112.49 10/27/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291210
Principal investigator 1 Ipsen Innovation $101.25 10/27/2025 Non-covered Recipient Entity
J Lewis Research, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291212
Principal investigator 1 Ipsen Innovation $956.34 10/27/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291214
Principal investigator 1 PFIZER INC. $148.60 10/27/2025 Non-covered Recipient Entity
J Lewis Res Foothill Clnc
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A BNT162B2 LP81ADAPTED VACCINE IN CHILDREN 5 THROUGH 11 YEARS OF AGE CONSIDERED AT HIGH RISK FOR SEVERE COVID19 No dispute reported 06/30/2026 1228723910
Principal investigator 1 PFIZER INC. $117.00 10/27/2025 Non-covered Recipient Entity
J Lewis Res Foothill Clnc
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A BNT162B2 LP81ADAPTED VACCINE IN CHILDREN 5 THROUGH 11 YEARS OF AGE CONSIDERED AT HIGH RISK FOR SEVERE COVID19 No dispute reported 06/30/2026 1228727827
Principal investigator 1 PFIZER INC. $88,011.70 10/25/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228743332
Principal investigator 1 Ipsen Innovation $90.00 10/23/2025 Non-covered Recipient Entity
J Lewis Research, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184294601
Principal investigator 1 SANOFI PASTEUR INC. $8,139.58 10/23/2025 Non-covered Recipient Entity
J Lewis Research,incorporation
A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers No dispute reported 06/30/2026 1226099570
Principal investigator 1 SANOFI PASTEUR INC. $5,209.66 10/23/2025 Non-covered Recipient Entity
J Lewis Research,incorporation
A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers No dispute reported 06/30/2026 1226099576
Principal investigator 1 SANOFI PASTEUR INC. $486.00 10/23/2025 Non-covered Recipient Entity
J Lewis Research,incorporation
A Phase 3 Randomized, Modified Double-blind, Active-controlled Study to Assess the Safety of vYF, Yellow Fever Vaccine, in Adults Aged 18 Years up to 60 Years No dispute reported 06/30/2026 1226099582
Principal investigator 1 SANOFI PASTEUR INC. $3,026.70 10/23/2025 Non-covered Recipient Entity
J Lewis Research,incorporation
A Phase 3 Randomized, Modified Double-blind, Active-controlled Study to Assess the Safety of vYF, Yellow Fever Vaccine, in Adults Aged 18 Years up to 60 Years No dispute reported 06/30/2026 1226099588
Principal investigator 1 ModernaTX, Inc. $14,628.60 10/22/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252963741
Principal investigator 1 PFIZER INC. $287.00 10/22/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic
A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228718755
Principal investigator 1 PFIZER INC. $272.70 10/17/2025 Non-covered Recipient Entity
JLewisFoothill Family Clinic
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE No dispute reported 06/30/2026 1228706979
Principal investigator 1 PFIZER INC. $172.34 10/17/2025 Non-covered Recipient Entity
JLewisFoothill Family Clinic
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE No dispute reported 06/30/2026 1228707149
Principal investigator 1 PFIZER INC. $12.31 10/17/2025 Non-covered Recipient Entity
JLewisFoothill Family Clinic
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE No dispute reported 06/30/2026 1228707151
Principal investigator 1 PFIZER INC. $39,487.50 10/11/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228742323
Principal investigator 1 ModernaTX, Inc. $4,800.00 10/03/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252963739
Principal investigator 1 SANOFI PASTEUR INC. $30,196.65 10/03/2025 Non-covered Recipient Entity
J Lewis Research,incorporation
A Phase 3 Randomized, Modified Double-blind, Active-controlled Study to Assess the Safety of vYF, Yellow Fever Vaccine, in Adults Aged 18 Years up to 60 Years No dispute reported 06/30/2026 1226099557
Principal investigator 1 ModernaTX, Inc. $11,511.06 10/01/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine No dispute reported 06/30/2026 1252963699
Principal investigator 1 PFIZER INC. $861.00 10/01/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic
A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228718417
Principal investigator 1 Ipsen Innovation $90.00 09/29/2025 Non-covered Recipient Entity
J Lewis Research, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184294591
Principal investigator 1 Ipsen Innovation $150.00 09/29/2025 Non-covered Recipient Entity
J Lewis Research, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184294593
Principal investigator 1 PFIZER INC. $530.25 09/29/2025 Non-covered Recipient Entity
JLewisFoothill Family Clinic
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE No dispute reported 06/30/2026 1228739573
Principal investigator 1 PFIZER INC. $430.85 09/29/2025 Non-covered Recipient Entity
JLewisFoothill Family Clinic
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE No dispute reported 06/30/2026 1228739634
Principal investigator 1 PFIZER INC. $22,975.00 09/27/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228762498
Principal investigator 1 PFIZER INC. $1,722.00 09/24/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic
A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228718419
Principal investigator 1 PFIZER INC. $615.50 09/24/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228719933
Principal investigator 1 PFIZER INC. $660.50 09/24/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228748149
Principal investigator 1 PFIZER INC. $14,175.00 09/24/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228758717
Principal investigator 1 ModernaTX, Inc. $7,925.18 09/19/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252963663
Principal investigator 1 ModernaTX, Inc. $360.00 09/17/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252963667
Principal investigator 1 PFIZER INC. $2,602.80 09/17/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE No dispute reported 06/30/2026 1228759101
Principal investigator 1 PFIZER INC. $2,392.62 09/10/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE No dispute reported 06/30/2026 1228768845
Principal investigator 1 PFIZER INC. $17,212.50 09/09/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228758899
Principal investigator 1 ModernaTX, Inc. $250.00 09/03/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252963727
Principal investigator 1 Ipsen Innovation $180.00 09/02/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184294595
Principal investigator 1 Ipsen Innovation $150.00 09/02/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184294597
Principal investigator 1 Ipsen Innovation $150.00 09/02/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184294599
Principal investigator 1 Ipsen Innovation $956.34 08/28/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291168
Principal investigator 1 Ipsen Innovation $956.34 08/28/2025 Non-covered Recipient Entity
J Lewis Research, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291182
Principal investigator 1 ModernaTX, Inc. $59.28 08/28/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253004745
Principal investigator 1 ModernaTX, Inc. $240.00 08/27/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252963685
Principal investigator 1 ModernaTX, Inc. $12,054.90 08/27/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine No dispute reported 06/30/2026 1252963701
Principal investigator 1 ModernaTX, Inc. $1,667.25 08/27/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine No dispute reported 06/30/2026 1252963703
Principal investigator 1 PFIZER INC. $10,551.80 08/27/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228785177
Principal investigator 1 Ipsen Innovation $2,539.55 08/25/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291150
Principal investigator 1 Ipsen Innovation $3,047.69 08/25/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291152
Principal investigator 1 Ipsen Innovation $3,047.69 08/25/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291156
Principal investigator 1 Ipsen Innovation $2,237.69 08/25/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291158
Principal investigator 1 Ipsen Innovation $3,047.69 08/25/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291160
Principal investigator 1 Ipsen Innovation $3,047.69 08/25/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291162
Principal investigator 1 Ipsen Innovation $3,047.69 08/25/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291164
Principal investigator 1 Ipsen Innovation $3,047.69 08/25/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291166
Principal investigator 1 Ipsen Innovation $3,047.69 08/25/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291170
Principal investigator 1 Ipsen Innovation $3,047.69 08/25/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291172
Principal investigator 1 Ipsen Innovation $2,382.41 08/25/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291174
Principal investigator 1 Ipsen Innovation $2,445.59 08/25/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291176
Principal investigator 1 Ipsen Innovation $5,338.03 08/25/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291180
Principal investigator 1 Ipsen Innovation $3,047.73 08/25/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291184
Principal investigator 1 ModernaTX, Inc. $7,321.73 08/22/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252963733
Principal investigator 1 Ipsen Innovation $3,047.69 08/14/2025 Non-covered Recipient Entity
J Lewis Research, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291154
Principal investigator 1 Ipsen Innovation $3,047.70 08/14/2025 Non-covered Recipient Entity
J Lewis Research, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291178
Principal investigator 1 PFIZER INC. $9,791.55 08/14/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE No dispute reported 06/30/2026 1228761660
Principal investigator 1 PFIZER INC. $88,548.75 08/09/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE No dispute reported 06/30/2026 1228786325
Principal investigator 1 ModernaTX, Inc. $160.00 08/06/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252963745
Principal investigator 1 PFIZER INC. $5,062.50 08/05/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228786166
Principal investigator 1 PFIZER INC. $14,134.00 08/02/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE No dispute reported 06/30/2026 1228789455
Principal investigator 1 PFIZER INC. $49,912.50 08/01/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228719707
Principal investigator 1 PFIZER INC. $10,759.20 07/31/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228765109
Principal investigator 1 Ipsen Innovation $956.34 07/28/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291142
Principal investigator 1 Ipsen Innovation $2,153.79 07/28/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291146
Principal investigator 1 Ipsen Innovation $1,848.15 07/28/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291148
Principal investigator 1 PFIZER INC. $4,875.96 07/26/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228724214
Principal investigator 1 Ipsen Innovation $300.00 07/25/2025 Non-covered Recipient Entity
J Lewis Research, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184294585
Principal investigator 1 ModernaTX, Inc. $26,938.58 07/25/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252963669
Principal investigator 1 Ipsen Innovation $221.33 07/17/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291144
Principal investigator 1 Ipsen Innovation $150.00 07/17/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184294587
Principal investigator 1 Ipsen Innovation $300.00 07/17/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184294589
Principal investigator 1 ModernaTX, Inc. $240.00 07/16/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252963729
Principal investigator 1 ModernaTX, Inc. $624.00 07/14/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253004737
Principal investigator 1 PFIZER INC. $13,449.00 07/11/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228764297
Principal investigator 1 PFIZER INC. $20,250.00 07/11/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228782098
Principal investigator 1 PFIZER INC. $123.10 07/10/2025 Non-covered Recipient Entity
JLewisFoothill Family Clinic
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE No dispute reported 06/30/2026 1228739630
Principal investigator 1 PFIZER INC. $151.50 07/10/2025 Non-covered Recipient Entity
JLewisFoothill Family Clinic
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE No dispute reported 06/30/2026 1228748047
Principal investigator 1 PFIZER INC. $98,872.03 07/08/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228781928
Principal investigator 1 ModernaTX, Inc. $2,926.20 07/02/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine No dispute reported 06/30/2026 1252963717
Principal investigator 1 ModernaTX, Inc. $350.00 07/02/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine No dispute reported 06/30/2026 1252963725
Principal investigator 1 PFIZER INC. $1,365.19 07/01/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228762986
Principal investigator 1 Ipsen Innovation $2,153.79 06/30/2025 Non-covered Recipient Entity
J Lewis Research, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291112
Principal investigator 1 Ipsen Innovation $956.34 06/30/2025 Non-covered Recipient Entity
J Lewis Research, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291114
Principal investigator 1 Ipsen Innovation $956.34 06/30/2025 Non-covered Recipient Entity
J Lewis Research, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291116
Principal investigator 1 Ipsen Innovation $2,005.56 06/30/2025 Non-covered Recipient Entity
J Lewis Research, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291118
Principal investigator 1 Ipsen Innovation $2,005.56 06/30/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291120
Principal investigator 1 Ipsen Innovation $956.34 06/30/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291124
Principal investigator 1 Ipsen Innovation $956.34 06/30/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291126
Principal investigator 1 Ipsen Innovation $956.34 06/30/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291128
Principal investigator 1 Ipsen Innovation $101.25 06/30/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291130
Principal investigator 1 Ipsen Innovation $956.34 06/30/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291132
Principal investigator 1 Ipsen Innovation $2,153.79 06/30/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291134
Principal investigator 1 Ipsen Innovation $1,182.33 06/30/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291138
Principal investigator 1 Ipsen Innovation $2,567.16 06/30/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291140
Principal investigator 1 PFIZER INC. $5,028.30 06/27/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228778159
Principal investigator 1 Ipsen Innovation $100.00 06/26/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291122
Principal investigator 1 PFIZER INC. $896.60 06/26/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228774166
Principal investigator 1 PFIZER INC. $18,146.70 06/26/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228777518
Principal investigator 1 SANOFI PASTEUR INC. $1,500.00 06/25/2025 Non-covered Recipient Entity
J Lewis Research,inc
Controlled Study of Immunogenicity and Safety of the Investigational vYF Candidate Vaccine in Comparison to YF-VAX in Adults No dispute reported 06/30/2026 1226100335
Principal investigator 1 SANOFI PASTEUR INC. $750.00 06/25/2025 Non-covered Recipient Entity
J Lewis Research,inc
Controlled Study of Immunogenicity and Safety of the Investigational vYF Candidate Vaccine in Comparison to YF-VAX in Adults No dispute reported 06/30/2026 1226100340
Principal investigator 1 Ipsen Innovation $16.94 06/23/2025 Non-covered Recipient Entity
J Lewis Research, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291136
Principal investigator 1 PFIZER INC. $10,031.85 06/21/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228777828
Principal investigator 1 ModernaTX, Inc. $13,694.40 06/18/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252963665
Principal investigator 1 ModernaTX, Inc. $448.30 06/18/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253004735
Principal investigator 1 PFIZER INC. $2,373.30 06/14/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228778300
Principal investigator 1 SANOFI PASTEUR INC. $2,604.83 06/12/2025 Non-covered Recipient Entity
J Lewis Research,incorporation
A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers No dispute reported 06/30/2026 1226099594
Principal investigator 1 PFIZER INC. $96,346.18 06/10/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228778625
Principal investigator 1 ModernaTX, Inc. $4,466.44 06/04/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine No dispute reported 06/30/2026 1252963679
Principal investigator 1 ModernaTX, Inc. $324.00 06/02/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine No dispute reported 06/30/2026 1252963651
Principal investigator 1 ModernaTX, Inc. $162.00 06/02/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine No dispute reported 06/30/2026 1252963721
Principal investigator 1 PFIZER INC. $12,465.90 05/30/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228771553
Principal investigator 1 Ipsen Innovation $400.00 05/29/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291110
Principal investigator 1 Ipsen Innovation $200.00 05/28/2025 Non-covered Recipient Entity
J Lewis Research, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291108
Principal investigator 1 ModernaTX, Inc. $80.00 05/28/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252963691
Principal investigator 1 ModernaTX, Inc. $46,623.20 05/28/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253004741
Principal investigator 1 ModernaTX, Inc. $9,321.78 05/28/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253004751
Principal investigator 1 ModernaTX, Inc. $12,330.24 05/28/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253004753
Principal investigator 1 SANOFI PASTEUR INC. $919.58 05/28/2025 Non-covered Recipient Entity
J Lewis Research,inc
Controlled Study of Immunogenicity and Safety of the Investigational vYF Candidate Vaccine in Comparison to YF-VAX in Adults No dispute reported 06/30/2026 1226100347
Principal investigator 1 PFIZER INC. $1,016.54 05/27/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228707864
Principal investigator 1 PFIZER INC. $1,016.54 05/27/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228761487
Principal investigator 1 PFIZER INC. $378.70 05/23/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228762798
Principal investigator 1 ModernaTX, Inc. $28,382.26 05/21/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252963659
Principal investigator 1 PFIZER INC. $72.61 05/21/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228706745
Principal investigator 1 PFIZER INC. $18.98 05/21/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228706747
Principal investigator 1 PFIZER INC. $72.61 05/21/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228762076
Principal investigator 1 PFIZER INC. $18.98 05/21/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228770610
Principal investigator 1 PFIZER INC. $3,600.00 05/21/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228783071
Principal investigator 1 ModernaTX, Inc. $229.50 05/16/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252963671
Principal investigator 1 ModernaTX, Inc. $300.00 05/16/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine No dispute reported 06/30/2026 1252963695
Principal investigator 1 PFIZER INC. $45,121.06 05/15/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228762901
Principal investigator 1 PFIZER INC. $2,700.00 05/08/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228782813
Principal investigator 1 PFIZER INC. $492.00 05/07/2025 Non-covered Recipient Entity
JLewis Foothill Family Clin S
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228768635
Principal investigator 1 PFIZER INC. $564.40 05/07/2025 Non-covered Recipient Entity
JLewis Foothill Family Clin S
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228771136
Principal investigator 1 ModernaTX, Inc. $3,235.32 05/02/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine No dispute reported 06/30/2026 1252963655
Principal investigator 1 SANOFI PASTEUR INC. $12,000.00 05/02/2025 Non-covered Recipient Entity
J Lewis Research,incorporation
A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers No dispute reported 06/30/2026 1226099542
Principal investigator 1 SANOFI PASTEUR INC. $2,500.00 05/02/2025 Non-covered Recipient Entity
J Lewis Research,incorporation
A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers No dispute reported 06/30/2026 1226099547
Principal investigator 1 PFIZER INC. $28,979.18 05/01/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228764731
Principal investigator 1 Ipsen Innovation $3,112.36 04/30/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291084
Principal investigator 1 SANOFI PASTEUR INC. $919.58 04/30/2025 Non-covered Recipient Entity
J Lewis Research,inc
Controlled Study of Immunogenicity and Safety of the Investigational vYF Candidate Vaccine in Comparison to YF-VAX in Adults No dispute reported 06/30/2026 1226100321
Principal investigator 1 SANOFI PASTEUR INC. $919.58 04/30/2025 Non-covered Recipient Entity
J Lewis Research,inc
Controlled Study of Immunogenicity and Safety of the Investigational vYF Candidate Vaccine in Comparison to YF-VAX in Adults No dispute reported 06/30/2026 1226100328
Principal investigator 1 Ipsen Innovation $956.34 04/28/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291054
Principal investigator 1 Ipsen Innovation $101.25 04/28/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291056
Principal investigator 1 Ipsen Innovation $956.34 04/28/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291058
Principal investigator 1 Ipsen Innovation $956.34 04/28/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291060
Principal investigator 1 Ipsen Innovation $956.34 04/28/2025 Non-covered Recipient Entity
J Lewis Research, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291064
Principal investigator 1 Ipsen Innovation $2,153.79 04/28/2025 Non-covered Recipient Entity
J Lewis Research, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291066
Principal investigator 1 Ipsen Innovation $956.34 04/28/2025 Non-covered Recipient Entity
J Lewis Research, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291068
Principal investigator 1 Ipsen Innovation $956.34 04/28/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291078
Principal investigator 1 Ipsen Innovation $2,005.56 04/28/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291080
Principal investigator 1 Ipsen Innovation $956.34 04/28/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291082
Principal investigator 1 Ipsen Innovation $956.34 04/28/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291088
Principal investigator 1 Ipsen Innovation $2,005.56 04/28/2025 Non-covered Recipient Entity
J Lewis Research, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291090
Principal investigator 1 Ipsen Innovation $956.34 04/28/2025 Non-covered Recipient Entity
J Lewis Research, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291092
Principal investigator 1 Ipsen Innovation $956.34 04/28/2025 Non-covered Recipient Entity
J Lewis Research, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291094
Principal investigator 1 Ipsen Innovation $956.34 04/28/2025 Non-covered Recipient Entity
J Lewis Research, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291096
Principal investigator 1 Ipsen Innovation $2,153.79 04/28/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291098
Principal investigator 1 Ipsen Innovation $956.34 04/28/2025 Non-covered Recipient Entity
J Lewis Research, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291100
Principal investigator 1 Ipsen Innovation $2,458.35 04/28/2025 Non-covered Recipient Entity
J Lewis Research, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291102
Principal investigator 1 Ipsen Innovation $956.34 04/28/2025 Non-covered Recipient Entity
J Lewis Research, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291104
Principal investigator 1 Ipsen Innovation $2,153.79 04/28/2025 Non-covered Recipient Entity
J Lewis Research, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291106
Principal investigator 1 ModernaTX, Inc. $34,967.40 04/28/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253004749
Principal investigator 1 ModernaTX, Inc. $15,536.30 04/28/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253004767
Principal investigator 1 ModernaTX, Inc. $18,179.20 04/28/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253004769
Principal investigator 1 SANOFI PASTEUR INC. $2,604.83 04/28/2025 Non-covered Recipient Entity
J Lewis Research,incorporation
A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers No dispute reported 06/30/2026 1226099552
Principal investigator 1 PFIZER INC. $595.82 04/25/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228722864
Principal investigator 1 PFIZER INC. $896.60 04/24/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228796714
Principal investigator 1 Ipsen Innovation $600.00 04/23/2025 Non-covered Recipient Entity
J Lewis Research, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291074
Principal investigator 1 Ipsen Innovation $180.00 04/23/2025 Non-covered Recipient Entity
J Lewis Research, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291076
Principal investigator 1 ModernaTX, Inc. $11,160.45 04/18/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252963689
Principal investigator 1 Ipsen Innovation $150.00 04/16/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291070
Principal investigator 1 Ipsen Innovation $270.00 04/16/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291072
Principal investigator 1 PFIZER INC. $6,019.82 04/16/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228794594
Principal investigator 1 Ipsen Innovation $500.00 04/14/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291062
Principal investigator 1 PFIZER INC. $6,921.04 04/10/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228779993
Principal investigator 1 PFIZER INC. $143.10 04/09/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228791695
Principal investigator 1 PFIZER INC. $7,172.80 04/08/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228724638
Principal investigator 1 ModernaTX, Inc. $654.75 04/04/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252963683
Principal investigator 1 ModernaTX, Inc. $100.00 04/02/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252963707
Principal investigator 1 ModernaTX, Inc. $10,831.51 04/02/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine No dispute reported 06/30/2026 1252963719
Principal investigator 1 Ipsen Innovation $350.00 04/01/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291086
Principal investigator 1 Ipsen Innovation $90.00 03/31/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291052
Principal investigator 1 PFIZER INC. $28,610.27 03/28/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228797815
Principal investigator 1 PFIZER INC. $823.50 03/26/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228779695
Principal investigator 1 ModernaTX, Inc. $1,965.60 03/24/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253004739
Principal investigator 1 ModernaTX, Inc. $1,344.90 03/24/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253004743
Principal investigator 1 ModernaTX, Inc. $2,545.14 03/24/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253004755
Principal investigator 1 ModernaTX, Inc. $21,750.82 03/24/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253004761
Principal investigator 1 ModernaTX, Inc. $187.20 03/24/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253004773
Principal investigator 1 ModernaTX, Inc. $16,183.44 03/24/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253004775
Principal investigator 1 PFIZER INC. $189.80 03/24/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228707862
Principal investigator 1 PFIZER INC. $189.80 03/23/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228769711
Principal investigator 1 PFIZER INC. $4,480.08 03/22/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228787498
Principal investigator 1 PFIZER INC. $4,168.00 03/22/2025 Non-covered Recipient Entity
J Lewis Research Inc
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS No dispute reported 06/30/2026 1228788993
Principal investigator 1 PFIZER INC. $24,776.55 03/22/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228795460
Principal investigator 1 ModernaTX, Inc. $7,670.02 03/21/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252963661
Principal investigator 1 ModernaTX, Inc. $240.00 03/21/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252963735
Principal investigator 1 PFIZER INC. $92,896.30 03/20/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228795420
Principal investigator 1 ModernaTX, Inc. $200.00 03/14/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine No dispute reported 06/30/2026 1252963675
Principal investigator 1 ModernaTX, Inc. $200.00 03/14/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine No dispute reported 06/30/2026 1252963697
Principal investigator 1 Ipsen Innovation $506.25 03/10/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291002
Principal investigator 1 Ipsen Innovation $405.00 03/10/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291004
Principal investigator 1 Ipsen Innovation $750.00 03/10/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291006
Principal investigator 1 Ipsen Innovation $47.79 03/10/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291008
Principal investigator 1 Ipsen Innovation $47.79 03/10/2025 Non-covered Recipient Entity
J Lewis Research, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291010
Principal investigator 1 Ipsen Innovation $47.79 03/10/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291014
Principal investigator 1 Ipsen Innovation $303.75 03/10/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291016
Principal investigator 1 Ipsen Innovation $47.79 03/10/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291018
Principal investigator 1 Ipsen Innovation $47.79 03/10/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291020
Principal investigator 1 Ipsen Innovation $607.50 03/10/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291022
Principal investigator 1 Ipsen Innovation $202.50 03/10/2025 Non-covered Recipient Entity
J Lewis Research, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291024
Principal investigator 1 Ipsen Innovation $150.00 03/10/2025 Non-covered Recipient Entity
J Lewis Research, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291026
Principal investigator 1 Ipsen Innovation $202.50 03/10/2025 Non-covered Recipient Entity
J Lewis Research, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291028
Principal investigator 1 Ipsen Innovation $47.79 03/10/2025 Non-covered Recipient Entity
J Lewis Research, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291030
Principal investigator 1 Ipsen Innovation $202.50 03/10/2025 Non-covered Recipient Entity
J Lewis Research, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291032
Principal investigator 1 Ipsen Innovation $47.79 03/10/2025 Non-covered Recipient Entity
J Lewis Research, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291034
Principal investigator 1 Ipsen Innovation $202.50 03/10/2025 Non-covered Recipient Entity
J Lewis Research, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291042
Principal investigator 1 PFIZER INC. $189.80 03/10/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228706743
Principal investigator 1 PFIZER INC. $189.80 03/10/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228770848
Principal investigator 1 Ipsen Innovation $3,047.71 03/06/2025 Non-covered Recipient Entity
J Lewis Research, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291012
Principal investigator 1 Ipsen Innovation $2,300.60 03/06/2025 Non-covered Recipient Entity
J Lewis Research, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291036
Principal investigator 1 Ipsen Innovation $3,047.69 03/06/2025 Non-covered Recipient Entity
J Lewis Research, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291038
Principal investigator 1 Ipsen Innovation $2,291.96 03/06/2025 Non-covered Recipient Entity
J Lewis Research, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291040
Principal investigator 1 Ipsen Innovation $3,047.69 03/06/2025 Non-covered Recipient Entity
J Lewis Research, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291044
Principal investigator 1 Ipsen Innovation $3,047.69 03/06/2025 Non-covered Recipient Entity
J Lewis Research, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291046
Principal investigator 1 Ipsen Innovation $3,047.69 03/06/2025 Non-covered Recipient Entity
J Lewis Research, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291048
Principal investigator 1 Ipsen Innovation $3,047.69 03/06/2025 Non-covered Recipient Entity
J Lewis Research, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291050
Principal investigator 1 PFIZER INC. $6,276.20 03/04/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228789497
Principal investigator 1 PFIZER INC. $14,600.00 03/04/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228789631
Principal investigator 1 ModernaTX, Inc. $27,794.60 02/27/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253004759
Principal investigator 1 ModernaTX, Inc. $18,218.72 02/27/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253004763
Principal investigator 1 ModernaTX, Inc. $20,197.19 02/27/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253004777
Principal investigator 1 ModernaTX, Inc. $19,821.38 02/26/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252963705
Principal investigator 1 PFIZER INC. $13,449.00 02/26/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228748889
Principal investigator 1 PFIZER INC. $6,447.19 02/26/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228762516
Principal investigator 1 PFIZER INC. $69,405.07 02/25/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228757096
Principal investigator 1 ModernaTX, Inc. $93.60 02/20/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253004733
Principal investigator 1 PFIZER INC. $487.35 02/19/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228759306
Principal investigator 1 PFIZER INC. $5,746.68 02/19/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228761323
Principal investigator 1 PFIZER INC. $472.50 02/14/2025 Non-covered Recipient Entity
J Lewis Research Inc
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS No dispute reported 06/30/2026 1228752166
Principal investigator 1 ModernaTX, Inc. $25,118.24 02/12/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults No dispute reported 06/30/2026 1252963693
Principal investigator 1 ModernaTX, Inc. $160.00 02/12/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252963743
Principal investigator 1 PFIZER INC. $28,633.50 02/12/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228757879
Principal investigator 1 PFIZER INC. $376.85 02/08/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228743646
Principal investigator 1 PFIZER INC. $2,350.00 02/04/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228707940
Principal investigator 1 ModernaTX, Inc. $976.05 02/03/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults No dispute reported 06/30/2026 1252963709
Principal investigator 1 ModernaTX, Inc. $361.05 02/03/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults No dispute reported 06/30/2026 1252963711
Principal investigator 1 ModernaTX, Inc. $11,594.35 02/03/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults No dispute reported 06/30/2026 1252963713
Principal investigator 1 PFIZER INC. $726.10 02/03/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228707936
Principal investigator 1 PFIZER INC. $317.00 02/03/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228707938
Principal investigator 1 PFIZER INC. $317.00 02/03/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228769715
Principal investigator 1 PFIZER INC. $726.10 02/03/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228770605
Principal investigator 1 PFIZER INC. $837.08 02/03/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228785091
Principal investigator 1 PFIZER INC. $981.24 02/03/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228786743
Principal investigator 1 SANOFI PASTEUR INC. $5,000.00 02/01/2025 Non-covered Recipient Entity
J Lewis Research,incorporation
Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) in Children and Adolescents Aged 9 to 17 Years and Adults Aged 18 to 49 Years. No dispute reported 06/30/2026 1226099526
Principal investigator 1 SANOFI PASTEUR INC. $3,000.00 02/01/2025 Non-covered Recipient Entity
J Lewis Research,incorporation
Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) in Children and Adolescents Aged 9 to 17 Years and Adults Aged 18 to 49 Years. No dispute reported 06/30/2026 1226099532
Principal investigator 1 SANOFI PASTEUR INC. $8,405.21 02/01/2025 Non-covered Recipient Entity
J Lewis Research,incorporation
Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) in Children and Adolescents Aged 9 to 17 Years and Adults Aged 18 to 49 Years. No dispute reported 06/30/2026 1226099537
Principal investigator 1 ModernaTX, Inc. $13,104.00 01/30/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253004757
Principal investigator 1 Ipsen Innovation $200.00 01/29/2025 Non-covered Recipient Entity
J Lewis Research, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184290998
Principal investigator 1 ModernaTX, Inc. $748.80 01/29/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine No dispute reported 06/30/2026 1252963657
Principal investigator 1 PFIZER INC. $478.71 01/29/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228801240
Principal investigator 1 PFIZER INC. $11,199.97 01/28/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228800258
Principal investigator 1 Ipsen Innovation $956.34 01/27/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184290982
Principal investigator 1 Ipsen Innovation $956.34 01/27/2025 Non-covered Recipient Entity
J Lewis Research, Inc
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291000
Principal investigator 1 ModernaTX, Inc. $11,539.84 01/27/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253004747
Principal investigator 1 ModernaTX, Inc. $27,965.34 01/27/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253004765
Principal investigator 1 ModernaTX, Inc. $17,932.00 01/27/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253004771
Principal investigator 1 PFIZER INC. $22,513.10 01/25/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228801660
Principal investigator 1 ModernaTX, Inc. $125.00 01/24/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252963687
Principal investigator 1 ModernaTX, Inc. $28,782.67 01/24/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252963731
Principal investigator 1 Ipsen Innovation $100.00 01/23/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184290996
Principal investigator 1 PFIZER INC. $5,165.63 01/22/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228798741
Principal investigator 1 PFIZER INC. $1,436.13 01/22/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228798771
Principal investigator 1 Ipsen Innovation $47.79 01/20/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184290984
Principal investigator 1 Ipsen Innovation $101.25 01/20/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184290986
Principal investigator 1 Ipsen Innovation $150.00 01/20/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184290988
Principal investigator 1 Ipsen Innovation $101.25 01/20/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184290992
Principal investigator 1 Ipsen Innovation $47.79 01/20/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184290994
Principal investigator 1 PFIZER INC. $2,562.70 01/15/2025 Non-covered Recipient Entity
J Lewis Research Inc
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS No dispute reported 06/30/2026 1228720071
Principal investigator 1 PFIZER INC. $1,436.13 01/15/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228801667
Principal investigator 1 PFIZER INC. $1,435.00 01/13/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic
A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228770601
Principal investigator 1 PFIZER INC. $13,199.12 01/09/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228800862
Principal investigator 1 Ipsen Innovation $180.00 01/08/2025 Non-covered Recipient Entity
J Lewis Research, Inc
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184290990
Principal investigator 1 PFIZER INC. $478.71 01/08/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228800238
Principal investigator 1 PFIZER INC. $1,435.00 01/06/2025 Non-covered Recipient Entity
J Lewis Research Inc Foothill Family Clinic
A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228707860
Principal investigator 1 ModernaTX, Inc. $160.00 01/03/2025 Non-covered Recipient Entity
J LEWIS RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252963673
Principal investigator 1 PFIZER INC. $478.71 01/01/2025 Non-covered Recipient Entity
J Lewis Research Inc
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228799409